NRx Pharmaceuticals logo
NRx Pharmaceuticals
NRXP | NASDAQ
Chart Builder DCF Calculator
$2.15
-$0.04 (-1.83%)
At close: Nov 16, 2026, 4:00 PM ET
$2.18
+$0.03 (+1.40%)
After-hours: Nov 16, 2026, 7:54 PM ET

NRx Pharmaceuticals Company Profile

Company profile explained

Company Profile

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.

Key Executives

Name Position
Jonathan C. Javitt Co-Founder, Chairman & CEO
Joseph Casper Chief Operating Officer
Dennis K. McBride Chief Strategy Officer & Director
Glenn Tyson Chief Commercial Officer
Hervé Perron Chief Scientist
Joshua C. Brown Chief Medical Innovation Officer
Michael S. Abrams CFO & Treasurer
Michael Taylor Chief Development Officer & Director
Philip T. Lavin Chief Methodologist
Riccardo Panicucci Chief Manufacturing & Technology Officer
Suzanne Messere Investor Relations

Latest SEC Filings

Date Type Title
Oct 16, 2026 8-K Current Report
Oct 05, 2026 8-K Current Report
Sep 16, 2026 8-K Current Report
Sep 14, 2026 8-K Current Report
Aug 17, 2026 8-K Current Report
Aug 14, 2026 10-Q Quarterly Report
Aug 07, 2026 8-K Current Report
Jul 22, 2026 8-K Current Report
Jun 04, 2026 8-K Current Report
Jun 02, 2026 8-K Current Report
View All SEC Filings ➞
NRx Pharmaceuticals
NRx Pharmaceuticals logo
Country United States
IPO Date Dec 4, 2017
Industry Biotechnology
Sector Healthcare
Employees 29
CEO Jonathan C. Javitt

Contact Details

1201 Orange Street Wilmington, Delaware 19801 United States

Stock Details

Ticker Symbol NRXP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001719406
CUSIP Number 629444209
ISIN Number US6294442099
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.